{"id":52485,"date":"2023-01-03T18:02:25","date_gmt":"2023-01-03T17:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/"},"modified":"2023-01-03T18:02:25","modified_gmt":"2023-01-03T17:02:25","slug":"rule-8-1-dealing-disclosure-horizon-therapeutics-plc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/","title":{"rendered":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (NASDAQ: HZNP):\n<\/p>\n

<\/a><\/p>\n

\nIRISH TAKEOVER PANEL<\/b>\n<\/p>\n

\nDEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022<\/b>\n<\/p>\n

\nBY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS<\/b>\n<\/p>\n

\n1. KEY INFORMATION<\/b>\n<\/p>\n\n\n\n\n\n\n\n
\n

\n(a) Full name of discloser:<\/b>\n<\/p>\n<\/td>\n

\n

\nJeff Himawan\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(b) Owner or controller of interests and short<\/b> positions disclosed, if different from 1(a):<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nThe naming of nominee or vehicle companies is<\/i> insufficient. For a trust, the trustee(s), settlor and<\/i> beneficiaries must be named.<\/i>\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(c) Name of offeror\/offeree in relation to whose<\/b> relevant securities this form relates:<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nUse a separate form for each offeror\/offeree<\/i>\n<\/p>\n<\/td>\n

\n

\nHorizon Therapeutics plc\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(d) Status of person making the disclosure:<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\ne.g. offeror, offeree, person acting in concert with the<\/i> offeror\/offeree (specify name of offeror\/offeree)<\/i>\n<\/p>\n<\/td>\n

\n

\nPerson acting in concert with the offeree (namely, a director of the offeree)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(e) Date dealing undertaken:<\/b>\n<\/p>\n<\/td>\n

\n

\nDecember 30, 2022\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(f) In addition to the company in 1(c) above, is the<\/b> discloser also making disclosures in respect of<\/b> any other party to the offer?<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nIf it is a cash offer or possible cash offer, state \u201cN\/A\u201d<\/i>\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n2. INTERESTS AND SHORT POSITIONS<\/b>\n<\/p>\n

\nIf there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.<\/i>\n<\/p>\n

\nInterests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing <\/b>(Note 1)\n<\/p>\n\n\n\n\n\n\n\n\n
\n

\nClass of relevant security:
\n
<\/b>(Note 2)\n<\/p>\n<\/td>\n

\n

\nOrdinary shares of US$0.0001 each
\n
(“Ordinary Shares<\/b>“)\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\nInterests<\/b>\n<\/p>\n<\/td>\n

\n

\nShort positions<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNumber<\/b>\n<\/p>\n<\/td>\n

\n

\n%<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber<\/b>\n<\/p>\n<\/td>\n

\n

\n%<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(1) Relevant securities owned<\/b> and\/or controlled:<\/b>\n<\/p>\n<\/td>\n

\n

\n147,382\n<\/p>\n<\/td>\n

\n

\n0.0649%\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(2) Cash-settled derivatives:<\/b>\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(3) Stock-settled derivatives<\/b> (including options) and<\/b> agreements to purchase\/sell:<\/b>\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal:<\/b>\n<\/p>\n<\/td>\n

\n

\n147,382\n<\/p>\n<\/td>\n

\n

\n0.0649%\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n

\n

\n–\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAll interests and all short positions should be disclosed.<\/i>\n<\/p>\n

\nDetails of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 .<\/i>\n<\/p>\n

\n3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE <\/b>(Note 3)\n<\/p>\n

\nWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.<\/i>\n<\/p>\n

\nThe currency of all prices and other monetary amounts should be stated.<\/i>\n<\/p>\n

\n(a) Purchases and sales<\/b>\n<\/p>\n

\n(i) Offeree, offeror or person acting in concert (except for a principal trader in the same group as a financial or other professional adviser acting in relation to the offer for the offeree or the offeror)<\/b>\n<\/p>\n\n\n\n
\n

\nClass of
\n
relevant
\n
security<\/b>\n<\/p>\n<\/td>\n

\n

\nPurchase\/sale<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber of
\n
securities<\/b>\n<\/p>\n<\/td>\n

\n

\nPrice per unit
\n
<\/b>(Note 4)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOrdinary shares\n<\/p>\n<\/td>\n

\n

\nSale (charitable donation)\n<\/p>\n<\/td>\n

\n

\n2,230\n<\/p>\n<\/td>\n

\n

\n$113.80\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a financial or other professional adviser acting in relation to the offer for the offeree or the offeror<\/b>\n<\/p>\n\n\n\n
\n

\nClass of
\n
relevant
\n
security<\/b>\n<\/p>\n<\/td>\n

\n

\nPurchases\/
\n
sales<\/b>\n<\/p>\n<\/td>\n

\n

\nTotal
\n
number of
\n
securities<\/b>\n<\/p>\n<\/td>\n

\n

\nHighest
\n
price per
\n
unit paid\/
\n
received<\/b>\n<\/p>\n<\/td>\n

\n

\nLowest
\n
price per
\n
unit paid\/
\n
received<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(b) Cash-settled derivative transactions<\/b>\n<\/p>\n\n\n\n
\n

\nClass of
\n
relevant
\n
security<\/b>\n<\/p>\n<\/td>\n

\n

\nProduct
\n
description
\n
<\/b>e.g. CFD<\/i>\n<\/p>\n<\/td>\n

\n

\nNature of
\n
dealing
\n
<\/b>e.g. opening\/<\/i>
closing a long\/
\n
short position,
\n
increasing\/
\n
reducing a long\/<\/i>
short position<\/i>\n<\/p>\n<\/td>\n

\n

\nNumber of
\n
reference
\n
securities
\n
<\/b>(Note 5)\n<\/p>\n<\/td>\n

\n

\nPrice
\n
per unit
\n
<\/b>(Note 4)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(c) Stock-settled derivative transactions (including options)<\/b>\n<\/p>\n

\n(i) Writing, selling, purchasing or varying<\/b>\n<\/p>\n\n\n\n
\n

\nClass of<\/b>
relevant<\/b>
security<\/b>\n<\/p>\n<\/td>\n

\n

\nProduct<\/b>
description<\/b>
e.g. call<\/i>
option<\/i>\n<\/p>\n<\/td>\n

\n

\nWriting,
\n
purchasing,<\/b>
selling,<\/b>
varying etc.<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber
\n
of<\/b>
securities<\/b>
to which<\/b>
option<\/b>
relates<\/b>
(Note 5)\n<\/p>\n<\/td>\n

\n

\nExercise<\/b>
price per<\/b>
<\/i>unit<\/b>\n<\/p>\n<\/td>\n

\n

\nType
\n
<\/b>e.g.<\/i>
American,<\/i>
European<\/i>
etc.<\/i>\n<\/p>\n<\/td>\n

\n

\nExpiry<\/b>
date<\/b>\n<\/p>\n<\/td>\n

\n

\nOption<\/b>
money<\/b>
paid\/<\/b>
received<\/b>
per unit<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(ii) Exercise<\/b>\n<\/p>\n\n\n\n
\n

\nClass of<\/b>
relevant<\/b>
security<\/b>\n<\/p>\n<\/td>\n

\n

\nProduct<\/b>
description<\/b>
e.g. call<\/i>
option<\/i>\n<\/p>\n<\/td>\n

\n

\nExercising\/<\/b>
exercised<\/b>
against<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber of<\/b>
securities<\/b>\n<\/p>\n<\/td>\n

\n

\nExercise<\/b>
price<\/b>
per unit<\/b>
(Note 4)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(d) Other dealings (including transactions in respect of new securities)<\/b>\n<\/p>\n\n\n\n
\n

\nClass of<\/b>
relevant<\/b>
security<\/b>\n<\/p>\n<\/td>\n

\n

\nNature of dealing<\/b>
e.g. subscription,<\/i>
conversion, exercise<\/i>\n<\/p>\n<\/td>\n

\n

\nDetails<\/b>\n<\/p>\n<\/td>\n

\n

\nPrice per unit<\/b>
(if applicable)<\/b>
(Note 4)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n4. OTHER INFORMATION<\/b>\n<\/p>\n

\n(a) Indemnity and other dealing arrangements<\/b>\n<\/p>\n\n\n\n
\n

\nDetails of any indemnity or option arrangement, or any agreement<\/b> or understanding, formal or informal, relating to relevant securities<\/b> which may be an inducement to deal or refrain from dealing<\/b> entered into by the party to the offer or person acting in concert<\/b> making the disclosure and any other person:<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nIrrevocable commitments and letters of intent should not be included. If<\/i> there are no such agreements, arrangements or understandings, state<\/i> \u201cnone\u201d<\/i>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(b) Agreements, arrangements or understandings relating to options or derivatives<\/b>\n<\/p>\n\n\n\n
\n

\nFull details of any agreement, arrangement or understanding<\/b> between the person disclosing and any other person relating to the<\/b> voting rights of any relevant securities under any option referred to<\/b> on this form or relating to the voting rights or future acquisition or<\/b> disposal of any relevant securities to which any derivative referred<\/b> to on this form is referenced. If none, this should be stated.<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(c) Attachments<\/b>\n<\/p>\n\n\n\n
\n

\nIs a Supplemental Form 8 attached?<\/b>\n<\/p>\n<\/td>\n

\n

\nYES\/NO<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nNo\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n
\n

\nDate of disclosure:<\/b>\n<\/p>\n<\/td>\n

\n

\nJanuary 3, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nContact name:<\/b>\n<\/p>\n<\/td>\n

\n

\nAidan Milstead\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTelephone number:<\/b>\n<\/p>\n<\/td>\n

\n

\n+1 224 206 4983\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPublic disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.<\/i>\n<\/p>\n

\nNOTES ON FORM 8.1(c) and (d)(i)\n<\/p>\n

\n1. See the definition of \u201cinterest in a relevant security\u201d in Rule 2.5 of Part A of the Rules and see Rule 8.6(b) of Part B of the Rules.<\/i>\n<\/p>\n

\n2. See the definition of \u201crelevant securities\u201d in Rule 2.1 of Part A of the Rules.<\/i>\n<\/p>\n

\n3. See the definition of \u201cdealing\u201d in Rule 2.1 of Part A of the Rules.<\/i>\n<\/p>\n

\n4. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.<\/i>\n<\/p>\n

\n5. See Rule 2.5(d) of Part A of the Rules.<\/i>\n<\/p>\n

\n6. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.<\/i>\n<\/p>\n

\nFor full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.<\/i>\n<\/p>\n

\nReferences in these notes to \u201cthe Rules\u201d are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAidan Milstead
\n
1.224.206.4983
\n
amilstead@horizontherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52485","6":"format-standard","7":"category-industry"},"yoast_head":"\nRule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T17:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)\",\"datePublished\":\"2023-01-03T17:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/\"},\"wordCount\":1132,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005641\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/\",\"name\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005641\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"datePublished\":\"2023-01-03T17:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005641\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230103005641\\\/en\\\/1460023\\\/21\\\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/","og_locale":"en_US","og_type":"article","og_title":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend","og_description":"DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-03T17:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)","datePublished":"2023-01-03T17:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/"},"wordCount":1132,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/","url":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/","name":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","datePublished":"2023-01-03T17:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230103005641\/en\/1460023\/21\/Horizon_Logo_Full-Color_RGB_Registered_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52485"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52485\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}